Tumor and Peripheral Immune Status in Soft Tissue Sarcoma: Implications for Immunotherapy

Area of Science:

• Oncology
• Immunology
• Cancer Research

Background:

• Soft Tissue Sarcomas (STS) are rare and heterogeneous tumors.
• The tumor microenvironment, including immune cells and factors, plays a critical role in STS.
• Current understanding of the immune system's role in STS prognosis and treatment is limited.

Purpose of the Study:

• To review the current knowledge on the immune microenvironment in Soft Tissue Sarcomas.
• To identify immune markers in the tumor microenvironment and peripheral blood associated with STS prognosis.
• To highlight the potential of immunotherapeutic approaches for STS.

Main Methods:

• Review of scientific literature on immune cells, soluble factors, and immune checkpoints in STS.
• Analysis of prognostic markers including tumor-infiltrating immune cells and peripheral blood immune status.
• Examination of immune-related gene expression in STS.

Main Results:

• Certain immune cells like B cells, NK cells, TANs, and DCs correlate with better outcomes, while TAMs are associated with poor outcomes.
• Elevated LMR, NLR, M-MDSCs, and Tim-3+ CD8 T cells are negative prognostic markers, whereas NKG2D+ CD8 T cells indicate a better prognosis.
• Soluble factors and immune checkpoint expression also show prognostic relevance in STS.

Conclusions:

• The immune microenvironment significantly influences STS prognosis and response to therapy.
• Peripheral blood immune status offers potential prognostic value in STS.
• Further research is essential to fully elucidate the immune system's role and develop novel immunotherapies for STS.